MARKET

EBS

EBS

Emergent Biosolutions Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

33.33
-3.34
-9.11%
Closed 19:59 05/24 EDT
OPEN
35.53
PREV CLOSE
36.67
HIGH
36.27
LOW
32.94
VOLUME
1.37M
TURNOVER
--
52 WEEK HIGH
68.03
52 WEEK LOW
27.61
MARKET CAP
1.67B
P/E (TTM)
11.33
1D
5D
1M
3M
1Y
5Y
7 Monkeypox Stocks to Watch Right Now
Investor Place · 15h ago
Monkeypox cases rise prompting vaccinations in U.S., Britain, and Germany
Countries from the U.S. to Germany are planning to offer monkeypox vaccinations as the rare viral disease continues to spread outside Central and West Africa, where it is usually detected.
Seekingalpha · 16h ago
SNGX: Phase 2a Trial of SGX302 in Psoriasis to Initiate in Second Half of 2022…
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT
Benzinga · 18h ago
Company News for May 24, 2022
Companies In The News Are: JPM, VMW, AVGO, EA, EBS.
Zacks · 20h ago
WHO Says Monkeypox Outbreak 'Unusual' But 'Containable'
The World Health Organization (WHO) said that there had been 131 confirmed monkeypox cases and 106 further suspected cases, 
Benzinga · 22h ago
Moderna enters monkeypox vaccine development
The COVID-19 vaccine maker Moderna (NASDAQ:MRNA) announces that the company is currently investigating potential monkeypox vaccines at a pre-clinical stage. The Cambridge, Massachusetts-based biotech made the statement at a time when the
Seekingalpha · 22h ago
CDC outlines stocks of vaccines available for monkeypox treatment
The CDC said that it has over 1K doses of the Jynneos vaccine, made by Bavarian Nordic (OTCPK:BVNKF) (OTCPK:BVNRY), in the national stockpile and will release some of it soon,
Seekingalpha · 1d ago
Hot Stocks: EBS rises on monkeypox fears; NTNX takeover speculation; NIU drops on earnings; SNOW price target cut
Takeover speculation and monkeypox concerns stirred trading in individual stocks during Monday's midday action. Nutanix (NTNX) received a boost from conjecture that it could become a takeover target for private
Seekingalpha · 1d ago
More
No Data
Learn about the latest financial forecast of EBS. Analyze the recent business situations of Emergent Biosolutions Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

12.50%Strong Buy
25.00%Buy
62.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average EBS stock price target is 44.33 with a high estimate of 65.00 and a low estimate of 30.00.
High65.00
Average44.33
Low30.00
Current 33.33
EPS
Actual
Estimate
0.842.033.234.43
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 361
Institutional Holdings: 48.73M
% Owned: 96.99%
Shares Outstanding: 50.24M
TypeInstitutionsShares
Increased
75
3.66M
New
45
1.26M
Decreased
92
4.14M
Sold Out
43
699.08K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.78%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
Zsolt Harsanyi
President/Chief Executive Officer/Director
Robert Kramer
Chief Financial Officer/Executive Vice President/Treasurer
Richard Lindahl
Chief Operating Officer/Executive Vice President
Adam Havey
Chief Human Resource Officer/Executive Vice President
Katherine Strei
Executive Vice President/General Counsel/Secretary
Jennifer Fox
Executive Vice President
Coleen Glessner
Executive Vice President
Atul Saran
Independent Director
Jerome Hauer
Independent Director
George Joulwan
Independent Director
Keith Katkin
Independent Director
Ronald Richard
Independent Director
Louis Sullivan
Independent Director
Marvin White
Independent Director
Kathryn Zoon
No Data
No Data
About EBS
Emergent BioSolutions Inc. is a life sciences company focused on providing civilian and military populations with a portfolio of preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats (PHTs). The Company is focused on five PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; acute/emergency care; and contract development and manufacturing (CDMO). It operates through four business units, which includes three product business units: Vaccines, Devices, Therapeutics; and one services business unit: CDMO. The Company's contract development and manufacturing service offerings cover development services, drug substance manufacturing and drug product manufacturing across the pharmaceutical and biotechnology industries as well as the United States Government (USG) and non-Governmental organizations.

Webull offers kinds of Emergent Biosolutions Inc stock information, including NYSE:EBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EBS stock methods without spending real money on the virtual paper trading platform.